id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
17965530_2 | We concluded that the colonic ulcer and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and sorbitol. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[77]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"calcium polystyrene sulfonate and sorbitol\"]], \"start\": [[109]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"calcium polystyrene sulfonate\"], [\"sorbitol\"]], \"start\": [[109], [143]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[139]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"sorbitol\"], [\"calcium polystyrene sulfonate\"]], \"start\": [[143], [109]], \"entity_id\": [\"T11\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"colonic ulcer and the sigmoidovesical fistula\"]], \"start\": [[22]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
15606443_2 | Rosiglitazone, a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus, is predominantly metabolized by the cytochrome P450 (CYP) enzyme CYP2C8. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"used\"]], \"start\": [[59]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Rosiglitazone\", \"a thiazolidinedione antidiabetic medication\"]], \"start\": [[0, 15]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Rosiglitazone\"], [\"thiazolidinedione antidiabetic medication\"]], \"start\": [[0], [17]], \"entity_id\": [\"T8\", \"T9\"]}, \"Disorder\": {\"text\": [[\"Type 2 diabetes mellitus\"]], \"start\": [[84]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
17873198_1 | Interstitial lung disease (ILD) related to therapy with the drug gefitinib has been well reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Interstitial lung disease (ILD)\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"therapy with the drug gefitinib\"]], \"start\": [[43]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"gefitinib\"]], \"start\": [[65]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
19540093_1 | According to the Naranjo adverse drug reaction probability scale, tigecycline was the probable cause of her acute pancreatitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[95]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"acute pancreatitis\"]], \"start\": [[108]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"tigecycline\"]], \"start\": [[66]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"tigecycline\"]], \"start\": [[66]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"probable\"]], \"start\": [[86]], \"entity_id\": [\"T5\"], \"value\": true}}"
}
]
}
] |
15479299_2 | We report a case of severe anemia, which responded well to steroid therapy, in a patient receiving IL-2 plus IFN-alpha for metastatic renal cell carcinoma. | true | [
{
"events": [
{
"event_id": "E3",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[89]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"IL-2 plus IFN-alpha\"]], \"start\": [[99]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"metastatic renal cell carcinoma\"]], \"start\": [[123]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"IL-2\"], [\"IFN-alpha\"]], \"start\": [[99], [109]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"plus\"]], \"start\": [[104]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"IFN-alpha\"], [\"IL-2\"]], \"start\": [[109], [99]], \"entity_id\": [\"T11\", \"T10\"]}}]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[79]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"severe anemia\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[20]], \"entity_id\": [\"T13\"], \"value\": \"High\"}}"
},
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"responded\"]], \"start\": [[41]], \"entity_id\": [\"T18\"]}, \"Treatment\": {\"text\": [[\"steroid\"]], \"start\": [[59]], \"entity_id\": [\"T16\"], \"Disorder\": {\"text\": [[\"severe anemia\"]], \"start\": [[20]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"steroid\"]], \"start\": [[59]], \"entity_id\": [\"T17\"]}}}"
}
]
}
] |
17420198_17 | The patient's movements resolved following diphenhydramine administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolved\"]], \"start\": [[24]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"diphenhydramine\"]], \"start\": [[43]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"diphenhydramine\"]], \"start\": [[43]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"movements\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}}}"
}
]
}
] |
10679548_5 | The spectrum of nitrofurantoin lung injury continues to widen. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"widen\"]], \"start\": [[56]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"lung injury\"]], \"start\": [[31]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[16]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[16]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
12243603_10 | We describe a patient with a complex medication regimen who was admitted for rhabdomyolysis and accompanying acute renal failure, along with acute hepatitis, thought to be secondary to a drug interaction between atorvastatin and diltiazem. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary\"]], \"start\": [[172]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"atorvastatin\", \"diltiazem\"]], \"start\": [[212, 229]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"atorvastatin\"], [\"diltiazem\"]], \"start\": [[212], [229]], \"entity_id\": [\"T14\", \"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[192]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"atorvastatin\"], [\"diltiazem\"]], \"start\": [[212], [229]], \"entity_id\": [\"T14\", \"T15\"]}}]}, \"Effect\": {\"text\": [[\"rhabdomyolysis and accompanying acute renal failure, along with acute hepatitis\"]], \"start\": [[77]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
11077455_4 | The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"attributed\"]], \"start\": [[118]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"vigabatrin\"]], \"start\": [[107]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"vigabatrin\"]], \"start\": [[107]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"visual field loss\"]], \"start\": [[129]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"eight patients\"]], \"start\": [[81]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"eight\"]], \"start\": [[81]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10840527_1 | Although the literature on the use of risperidone in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms (EPS). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"is\"]], \"start\": [[185]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"use of risperidone\"]], \"start\": [[31]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"risperidone\"]], \"start\": [[38]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"dementia\"]], \"start\": [[75]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"elderly patients with dementia\"]], \"start\": [[53]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[53]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
18294121_4 | Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Temozolomide\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Temozolomide\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"metastatic melanoma\"]], \"start\": [[62]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"desquamative skin rash\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with metastatic melanoma\"]], \"start\": [[47]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
4066622_2 | The calcium channel blockers are a group of drugs that have recently become available for the treatment of angina. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[94]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"calcium channel blockers\"]], \"start\": [[4]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"angina\"]], \"start\": [[107]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"calcium channel blockers\"]], \"start\": [[4]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10723699_2 | We report on a young adolescent with benign intracranial hypertension which we attribute to the use of minocycline for acne. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"attribute\"]], \"start\": [[79]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"minocycline\"]], \"start\": [[103]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"minocycline\"]], \"start\": [[103]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"acne\"]], \"start\": [[119]], \"entity_id\": [\"T14\"]}}, \"Subject\": {\"text\": [[\"a young adolescent\"]], \"start\": [[13]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"young adolescent\"]], \"start\": [[15]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"benign intracranial hypertension\"]], \"start\": [[37]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
18795_1 | A 10-year-old asthmatic boy began to suffer from urticarial rash and moderately severe bronchospasm after 8 weeks' treatment with disodium cromoglycate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[100]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A 10-year-old asthmatic boy\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"10-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"boy\"]], \"start\": [[24]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"urticarial rash and moderately severe bronchospasm\"]], \"start\": [[49]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"8 weeks' treatment with disodium cromoglycate\"]], \"start\": [[106]], \"entity_id\": [\"T8\"], \"Time_elapsed\": {\"text\": [[\"8 weeks'\"]], \"start\": [[106]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"disodium cromoglycate\"]], \"start\": [[130]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"asthmatic\"]], \"start\": [[14]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
2796025_1 | Panic anxiety after abrupt discontinuation of mianserin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[14]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Panic anxiety\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"abrupt discontinuation of mianserin\"]], \"start\": [[20]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"mianserin\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
17873198_4 | This case and other published evidence should alert physicians to the possibility of fatal erlotinib-induced ILD. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[101]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"This case\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"erlotinib\"]], \"start\": [[91]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"erlotinib\"]], \"start\": [[91]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"ILD\"]], \"start\": [[109]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"possibility\"]], \"start\": [[70]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
17987285_3 | Recent reports suggest that concomitant administration of CYP3A inhibitors with fentanyl may lead to dangerous drug interactions. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"lead\"]], \"start\": [[93]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"concomitant administration of CYP3A inhibitors with fentanyl\"]], \"start\": [[28]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"CYP3A inhibitors\"], [\"fentanyl\"]], \"start\": [[58], [80]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concomitant\"]], \"start\": [[28]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"CYP3A inhibitors\"], [\"fentanyl\"]], \"start\": [[58], [80]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"drug interactions\"]], \"start\": [[111]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[89]], \"entity_id\": [\"T12\"], \"value\": true}, \"Severity\": {\"text\": [[\"dangerous\"]], \"start\": [[101]], \"entity_id\": [\"T14\"], \"value\": \"High\"}}"
}
]
}
] |
21751666_4 | Post-exposure prophylaxis of H1N1 with oseltamivir was safe, effective and well tolerated to prevent H1N1 influenza A virus infection in newly transplanted renal allograft recipient receiving triple immunosuppression without any interaction with tacrolimus level. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prophylaxis\"]], \"start\": [[14]], \"entity_id\": [\"T13\"]}, \"Subject\": {\"text\": [[\"newly transplanted renal allograft recipient\"]], \"start\": [[137]], \"entity_id\": [\"T15\"], \"Disorder\": {\"text\": [[\"transplanted renal allograft\"]], \"start\": [[143]], \"entity_id\": [\"T17\"]}}, \"Treatment\": {\"text\": [[\"oseltamivir\", \"without any interaction with tacrolimus level\"]], \"start\": [[39, 217]], \"entity_id\": [\"T12\"], \"Disorder\": {\"text\": [[\"H1N1\"]], \"start\": [[29]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"oseltamivir\"], [\"tacrolimus\"]], \"start\": [[39], [246]], \"entity_id\": [\"T19\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E3\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[229]], \"entity_id\": [\"T24\"]}, \"Drug\": {\"text\": [[\"tacrolimus\"], [\"oseltamivir\"]], \"start\": [[246], [39]], \"entity_id\": [\"T14\", \"T19\"]}}]}, \"Effect\": {\"text\": [[\"safe, effective and well tolerated to prevent H1N1 influenza A virus infection\"]], \"start\": [[55]], \"entity_id\": [\"T21\"]}}"
}
]
}
] |
8672829_3 | DISCUSSION: Central nervous system (CNS) toxicity has been described with ifosfamide, with most cases reported in the pediatric population. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"described\"]], \"start\": [[59]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"in the pediatric population\"]], \"start\": [[111]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"pediatric\"]], \"start\": [[118]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"ifosfamide\"]], \"start\": [[74]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"ifosfamide\"]], \"start\": [[74]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Central nervous system (CNS) toxicity\"]], \"start\": [[12]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12796597_2 | Despite the underlying hepatitis C, this case represents renal abnormalities consistent with IFNalpha therapy for CML. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"consistent\"]], \"start\": [[77]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"renal abnormalities\"]], \"start\": [[57]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"this case\"]], \"start\": [[36]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"IFNalpha therapy\"]], \"start\": [[93]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"IFNalpha\"]], \"start\": [[93]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"CML\"]], \"start\": [[114]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
11131346_4 | CONCLUSION: To the best of our knowledge, this is the first time colchicine intoxication in this age group has been described in the English literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"intoxication\"]], \"start\": [[76]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"colchicine\"]], \"start\": [[65]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"colchicine\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"colchicine intoxication\"]], \"start\": [[65]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
85289_2 | We have seen a case of terminal malignant melanoma in which clinical manifestations, indicative of anterior spinal artery syndrome, developed following the injection of 0.3 ml of 10% phenol-glycerine into the cervical subarachnoid space at the C4--C5 level for the control of severe right arm pain. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[132]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"terminal malignant melanoma in which clinical manifestations, indicative of anterior spinal artery syndrome\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"the injection of 0.3 ml of 10% phenol-glycerine into the cervical subarachnoid space at the C4--C5 level\"]], \"start\": [[152]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"10% phenol-glycerine\"]], \"start\": [[179]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"severe right arm pain\"]], \"start\": [[276]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"injection\"], [\"cervical subarachnoid space at the C4--C5 level\"]], \"start\": [[156], [209]], \"entity_id\": [\"T9\", \"T11\"]}, \"Dosage\": {\"text\": [[\"0.3 ml\"]], \"start\": [[169]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
10904571_2 | Colchicine-induced myopathy in renal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Colchicine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Colchicine\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"renal failure\"]], \"start\": [[31]], \"entity_id\": [\"T4\"]}}, \"Effect\": {\"text\": [[\"myopathy\"]], \"start\": [[19]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
7679525_4 | This report suggests that bleomycin lung toxicity may be reversible if treated aggressively. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"toxicity\"]], \"start\": [[41]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"bleomycin\"]], \"start\": [[26]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"bleomycin\"]], \"start\": [[26]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"lung toxicity\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[50]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
15840734_8 | DISCUSSION: NMS is a rare but potentially fatal reaction associated with neuroleptic drugs. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[57]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"neuroleptic drugs\"]], \"start\": [[73]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"neuroleptic\"]], \"start\": [[73]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"NMS\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[42]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
1378497_3 | Scleroderma in association with the use of bleomycin: a report of 3 cases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Scleroderma\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"bleomycin\"]], \"start\": [[43]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"bleomycin\"]], \"start\": [[43]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"3 cases\"]], \"start\": [[66]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[66]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
19733945_1 | Linezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[10]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Linezolid\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Linezolid\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome\"]], \"start\": [[21]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
16012330_5 | A 3-year-old boy diagnosed with acute lymphoblastic leukemia received induction chemotherapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"received\"]], \"start\": [[61]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 3-year-old boy diagnosed with acute lymphoblastic leukemia\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"3-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"boy\"]], \"start\": [[13]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"induction chemotherapy\"]], \"start\": [[70]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"acute lymphoblastic leukemia\"]], \"start\": [[32]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"induction chemotherapy\"]], \"start\": [[70]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
17438184_8 | Interferon and other immunostimulatory medications can lead to an exacerbation of this preexisting low-grade chronic inflammation that is quite similar to interferon-triggered sarcoidosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"lead\"]], \"start\": [[55]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Interferon and other immunostimulatory medications\"]], \"start\": [[0]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"Interferon\"]], \"start\": [[0]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"exacerbation of this preexisting low-grade chronic inflammation\"]], \"start\": [[66]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
2768785_1 | Intravenous cytarabine and methotrexate appear to act synergistically to enhance the potential for central nervous system toxicity. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"enhance\"]], \"start\": [[73]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Intravenous cytarabine and methotrexate\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"methotrexate\"], [\"cytarabine\"]], \"start\": [[27], [12]], \"entity_id\": [\"T7\", \"T8\"]}, \"Route\": {\"text\": [[\"Intravenous\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[23]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"methotrexate\"], [\"cytarabine\"]], \"start\": [[27], [12]], \"entity_id\": [\"T7\", \"T8\"]}}]}, \"Effect\": {\"text\": [[\"central nervous system toxicity\"]], \"start\": [[99]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
12150593_3 | We suggest adding this side effect to the list of untoward effects of lidocaine and to the differential diagnosis of fixed dilated pupils in neonates treated with lidocaine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[150]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"lidocaine\"]], \"start\": [[163]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"lidocaine\"]], \"start\": [[163]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"neonates\"]], \"start\": [[141]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"neonates\"]], \"start\": [[141]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"side effect\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17444802_14 | CONCLUSIONS: Topical INF alpha 2-beta is a valid choice for the treatment of CIN in patients for whom surgery is not possible. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"a valid choice\"]], \"start\": [[41]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Topical INF alpha 2-beta\"]], \"start\": [[13]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"CIN\"]], \"start\": [[77]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"Topical\"]], \"start\": [[13]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"INF alpha 2-beta\"]], \"start\": [[21]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"patients for whom surgery is not possible\"]], \"start\": [[84]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
9247841_4 | We report 3 patients who developed cutaneous vasculitis which is a rare and serious side-effect during antithyroid drug therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"3 patients\"]], \"start\": [[10]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[10]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"cutaneous vasculitis\"]], \"start\": [[35]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"during antithyroid drug therapy\"]], \"start\": [[96]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"antithyroid\"]], \"start\": [[103]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
1621023_3 | Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[74]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Prominent eye movements during NREM sleep and REM sleep behavior disorder\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"fluoxetine treatment\"]], \"start\": [[90]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"fluoxetine\"]], \"start\": [[90]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"depression\"], [\"obsessive-compulsive disorder\"]], \"start\": [[114], [129]], \"entity_id\": [\"T12\", \"T13\"]}}, \"Subject\": {\"text\": [[\"depression and obsessive-compulsive disorder\"]], \"start\": [[114]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
10963515_1 | Allergic reaction to gemfibrozil manifesting as eosinophilic gastroenteritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"Allergic reaction\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"gemfibrozil\"]], \"start\": [[21]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"gemfibrozil\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"eosinophilic gastroenteritis\"]], \"start\": [[48]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
16432996_14 | We suggest that sarcoidosis may develop in chronic hepatitis C patients during interferon alpha and/or ribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[32]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"sarcoidosis\"]], \"start\": [[16]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"chronic hepatitis C patients\"]], \"start\": [[43]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"interferon alpha and/or ribavirin\"]], \"start\": [[79]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"chronic hepatitis C\"]], \"start\": [[43]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"interferon alpha\"], [\"ribavirin\"]], \"start\": [[79], [103]], \"entity_id\": [\"T14\", \"T15\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[28]], \"entity_id\": [\"T13\"], \"value\": true}}"
}
]
}
] |
25417855_2 | Azole antifungals, prescribed prophylactically to avoid severe infections in immunosuppressed organ transplant recipients, can interact with drug substrates of CYP3A4. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"interact\"]], \"start\": [[127]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"Azole antifungals\", \"drug substrates of CYP3A4\"]], \"start\": [[0, 141]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"severe infections\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"Azole antifungals\"], [\"drug substrates of CYP3A4\"]], \"start\": [[0], [141]], \"entity_id\": [\"T10\", \"T6\"]}, \"Combination\": [{\"event_id\": \"E3\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interact\"]], \"start\": [[127]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"drug substrates of CYP3A4\"], [\"Azole antifungals\"]], \"start\": [[141], [0]], \"entity_id\": [\"T6\", \"T10\"]}}]}, \"Subject\": {\"text\": [[\"immunosuppressed organ transplant recipients\"]], \"start\": [[77]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"immunosuppressed organ transplant\"]], \"start\": [[77]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
11576059_2 | We present the case of a 5-year-old girl who developed bilateral vocal cord paralysis following preoperative peritonsillar bupivacaine infiltration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[86]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a 5-year-old girl\"]], \"start\": [[23]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"5-year-old\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"girl\"]], \"start\": [[36]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"bilateral vocal cord paralysis\"]], \"start\": [[55]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"preoperative peritonsillar bupivacaine infiltration\"]], \"start\": [[96]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"bupivacaine\"]], \"start\": [[123]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"peritonsillar\", \"infiltration\"]], \"start\": [[109, 135]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
20338114_1 | One patient suffered coronary artery vasospasm, attributed to the use of topical 1:1000 epinephrine during surgery. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"attributed\"]], \"start\": [[48]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"topical 1:1000 epinephrine during surgery\"]], \"start\": [[73]], \"entity_id\": [\"T4\"], \"Dosage\": {\"text\": [[\"1:1000\"]], \"start\": [[81]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"epinephrine\"]], \"start\": [[88]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"coronary artery vasospasm\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"One patient\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"One\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
16396068_1 | Trimethoprim-sulfamethoxazole-induced aseptic meningitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[30]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"aseptic meningitis\"]], \"start\": [[38]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Trimethoprim-sulfamethoxazole\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Trimethoprim-sulfamethoxazole\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
9256906_4 | We describe a patient with metastatic prostate cancer who developed nonoliguric renal failure during treatment with suramin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[94]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"suramin\"]], \"start\": [[116]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"suramin\"]], \"start\": [[116]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"metastatic prostate cancer\"]], \"start\": [[27]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"a patient with metastatic prostate cancer\"]], \"start\": [[12]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"nonoliguric renal failure\"]], \"start\": [[68]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10656221_10 | In conclusion, this case strongly suggests that gliclazide can induce acute icteric liver necro-inflammation which may be misdiagnosed clinically as acute viral hepatitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induce\"]], \"start\": [[63]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"gliclazide\"]], \"start\": [[48]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"gliclazide\"]], \"start\": [[48]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"acute icteric liver necro-inflammation\"]], \"start\": [[70]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"this case\"]], \"start\": [[15]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"strongly suggests\"]], \"start\": [[25]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
15685264_7 | After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of Carbamazepine intoxication. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"After\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"she\"]], \"start\": [[93]], \"entity_id\": [\"T10\"], \"Gender\": {\"text\": [[\"she\"]], \"start\": [[93]], \"entity_id\": [\"T13\"]}}, \"Treatment\": {\"text\": [[\"Oxybutynin concomitantly with an increase in the dose of Dantrolene\", \"Carbamazepine\"]], \"start\": [[24, 155]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"Carbamazepine\"], [\"Oxybutynin\"], [\"Dantrolene\"]], \"start\": [[155], [24], [81]], \"entity_id\": [\"T14\", \"T15\", \"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[49]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"Oxybutynin\"], [\"Dantrolene\"]], \"start\": [[24], [81]], \"entity_id\": [\"T15\", \"T16\"]}}]}, \"Effect\": {\"text\": [[\"clinical symptoms and laboratory finding of Carbamazepine intoxication\"]], \"start\": [[111]], \"entity_id\": [\"T12\"]}}"
}
]
}
] |
21597286_4 | A methotrexate overdosage was shown at 36 h after infusion associated with a severe renal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[59]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"methotrexate overdosage was shown at 36 h after infusion\", \"severe renal failure\"]], \"start\": [[2, 77]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[2]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[77]], \"entity_id\": [\"T5\"], \"value\": \"Medium\"}}"
}
]
}
] |
18717612_1 | Ceftriaxone-induced fixed drug eruption: first report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Ceftriaxone\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Ceftriaxone\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"fixed drug eruption\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
7594371_4 | We report the case of a 20-year-old female with polyarteritis nodosa (PAN) who developed bilateral sensorineural hearing loss 25 minutes after receiving 30 mg of intravenous ketoralac. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[79]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"20-year-old female with polyarteritis nodosa (PAN)\"]], \"start\": [[24]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"20-year-old\"]], \"start\": [[24]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[36]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"bilateral sensorineural hearing loss\"]], \"start\": [[89]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"30 mg of intravenous ketoralac\"]], \"start\": [[153]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"polyarteritis nodosa\"]], \"start\": [[48]], \"entity_id\": [\"T10\"]}, \"Time_elapsed\": {\"text\": [[\"25 minutes after\"]], \"start\": [[126]], \"entity_id\": [\"T11\"]}, \"Dosage\": {\"text\": [[\"30 mg\"]], \"start\": [[153]], \"entity_id\": [\"T12\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[162]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"ketoralac\"]], \"start\": [[174]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
19915794_4 | We report an 82-year-old man who developed ventricular tachycardia and Torsades de Pointes (TdP) after oral administration of garenoxacin, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[97]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"oral administration of garenoxacin\"]], \"start\": [[103]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"pneumonia\"]], \"start\": [[229]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"oral\"]], \"start\": [[103]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"garenoxacin\"]], \"start\": [[126]], \"entity_id\": [\"T15\"]}}, \"Subject\": {\"text\": [[\"an 82-year-old man\"]], \"start\": [[10]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"82-year-old\"]], \"start\": [[13]], \"entity_id\": [\"T12\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[25]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"ventricular tachycardia and Torsades de Pointes (TdP)\"]], \"start\": [[43]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
12951892_1 | Lethargy in a newborn: lithium toxicity or lab error? | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"toxicity\"]], \"start\": [[31]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"lithium\"]], \"start\": [[23]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[23]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"Lethargy\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a newborn\"]], \"start\": [[12]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"newborn\"]], \"start\": [[14]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
18344455_1 | Simultaneous toxicities in a child on multiple anticonvulsants. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"on\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a child\"]], \"start\": [[27]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[29]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"multiple anticonvulsants.\"]], \"start\": [[38]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"anticonvulsants\"]], \"start\": [[47]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"Simultaneous toxicities\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
17404582_3 | We report a 71-year male with castration-resistant metastatic prostate cancer who was treated with weekly docetaxel for 12 weeks and developed significant eye irritation and dryness during treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[133]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"significant eye irritation and dryness\"]], \"start\": [[143]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a 71-year male with castration-resistant metastatic prostate cancer\"]], \"start\": [[10]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"71-year\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"weekly docetaxel for 12 weeks\"]], \"start\": [[99]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"castration-resistant metastatic prostate cancer\"]], \"start\": [[30]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"docetaxel\"]], \"start\": [[106]], \"entity_id\": [\"T10\"]}, \"Freq\": {\"text\": [[\"weekly\"]], \"start\": [[99]], \"entity_id\": [\"T11\"]}, \"Duration\": {\"text\": [[\"12 weeks\"]], \"start\": [[120]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
1621023_2 | In addition, a 31-year-old man with obsessive-compulsive disorder developed RBD soon after starting fluoxetine therapy, which persisted at PSG study 19 months after fluoxetine discontinuation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[66]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a 31-year-old man with obsessive-compulsive disorder\"]], \"start\": [[13]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"31-year-old\"]], \"start\": [[15]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[27]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"RBD\", \"which persisted at PSG study 19 months after fluoxetine discontinuation\"]], \"start\": [[76, 120]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"starting fluoxetine therapy\"]], \"start\": [[91]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"fluoxetine\"]], \"start\": [[100]], \"entity_id\": [\"T11\"]}, \"Time_elapsed\": {\"text\": [[\"soon after starting\"]], \"start\": [[80]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"obsessive-compulsive disorder\"]], \"start\": [[36]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
24791374_1 | Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[81]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Propafenone\", \"mirtazapine\"]], \"start\": [[0, 88]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"mirtazapine\"], [\"Propafenone\"]], \"start\": [[88], [0]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[123]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"Propafenone\"], [\"mirtazapine\"]], \"start\": [[0], [88]], \"entity_id\": [\"T13\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"central nervous system and cardiovascular toxicity\"]], \"start\": [[30]], \"entity_id\": [\"T11\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[23]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
582099_2 | Neurotoxicity of intrathecal administration of amphotericin B. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[14]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Neurotoxicity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intrathecal administration of amphotericin B\"]], \"start\": [[17]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"amphotericin B\"]], \"start\": [[47]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"intrathecal\"]], \"start\": [[17]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
7724306_6 | Parenteral pyridoxine, the specific antidote for INH-induced refractory seizures, should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[53]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"INH\"]], \"start\": [[49]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"INH\"]], \"start\": [[49]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"refractory seizures\"]], \"start\": [[61]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9220046_3 | DISCUSSION: Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with rhabdomyolysis, including lovastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[159]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"lovastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor\"]], \"start\": [[201]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"lovastatin\"]], \"start\": [[201]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure\"]], \"start\": [[12]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
20367573_2 | Thrombocytosis associated with enoxaparin: A very rare cause in newborns. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Thrombocytosis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"enoxaparin\"]], \"start\": [[31]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"enoxaparin\"]], \"start\": [[31]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"newborns\"]], \"start\": [[64]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"newborns\"]], \"start\": [[64]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
6837655_2 | The spectrum of renal lesions occurring during antituberculous therapy, particularly in association with rifampin, may be wider than previously suspected. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[40]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"antituberculous therapy, particularly in association with rifampin\"]], \"start\": [[47]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"rifampin\"], [\"antituberculous therapy\"]], \"start\": [[105], [47]], \"entity_id\": [\"T6\", \"T7\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[88]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"rifampin\"], [\"antituberculous therapy\"]], \"start\": [[105], [47]], \"entity_id\": [\"T6\", \"T7\"]}}]}, \"Effect\": {\"text\": [[\"The spectrum of renal lesions occurring\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
16960880_3 | Native arterial thrombosis, though recognized as a severe complication of thrombin injection, has not been well described in the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[58]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Native arterial thrombosis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"thrombin injection\"]], \"start\": [[74]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"thrombin\"]], \"start\": [[74]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"injection\"]], \"start\": [[83]], \"entity_id\": [\"T7\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[51]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
21512888_8 | After treatment with levetiracetam, seizures recurred and intravenous loading with valproic acid was administered, but resulted in a rapid increase in international normalized ratio (INR) to 7.6. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"recurred\"]], \"start\": [[45]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"levetiracetam\"]], \"start\": [[21]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"levetiracetam\"]], \"start\": [[21]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"seizures\"]], \"start\": [[36]], \"entity_id\": [\"T10\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"administered\"]], \"start\": [[101]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"intravenous loading with valproic acid\"]], \"start\": [[58]], \"entity_id\": [\"T12\"], \"Disorder\": {\"text\": [[\"seizures\"]], \"start\": [[36]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[58]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"valproic acid\"]], \"start\": [[83]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
18396749_1 | Acute hepatitis with prolonged cholestasis and disappearance of interlobular bile ducts following tibolone and Hypericum perforatum (St. John's wort). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[88]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"tibolone and Hypericum perforatum (St. John's wort)\"]], \"start\": [[98]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"tibolone\"], [\"Hypericum perforatum\"]], \"start\": [[98], [111]], \"entity_id\": [\"T9\", \"T10\"]}}, \"Effect\": {\"text\": [[\"Acute hepatitis with prolonged cholestasis and disappearance of interlobular bile ducts\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8002140_3 | METHODS: Five cases of contact dermatitis due to budesonide, a nonhalogenated steroid, are described. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[42]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"contact dermatitis\"]], \"start\": [[23]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"budesonide\"]], \"start\": [[49]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"budesonide\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"Five cases\"]], \"start\": [[9]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"Five\"]], \"start\": [[9]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
1124417_3 | This sulfonamide like nephropathy should be differentiated from acetazolamide-related calcium phosphate nephrolithiasis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[78]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"calcium phosphate nephrolithiasis.\"]], \"start\": [[86]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"acetazolamide\"]], \"start\": [[64]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"acetazolamide\"]], \"start\": [[64]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
17420198_18 | Aripiprazole was subsequently discontinued secondary to its lack of efficacy for OCD and the development of a movement disorder. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[93]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Aripiprazole\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"OCD\"]], \"start\": [[81]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"Aripiprazole\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"a movement disorder\"]], \"start\": [[108]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
12187348_1 | Gigantomastia induced by bucillamine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Gigantomastia\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"bucillamine\"]], \"start\": [[25]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"bucillamine\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
20038831_2 | Hypersensitivity to carboplatin has been reported in up to 44% of patients receiving this antineoplastic agent, usually occurring after several courses of treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[17]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"44% of patients\"]], \"start\": [[59]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Hypersensitivity\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"carboplatin\", \"after several courses of treatment\"]], \"start\": [[20, 130]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"carboplatin\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
8908396_1 | CONCLUSIONS: In our reported case, a local hyperproduction of TNF-alpha from macrophages that was induced by the injected insulin could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[98]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"injected insulin\"]], \"start\": [[113]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"injected\"]], \"start\": [[113]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"insulin\"]], \"start\": [[122]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"local hyperproduction of TNF-alpha from macrophages\", \"dedifferentiation of the adipocytes of the subcutaneous tissue\"]], \"start\": [[37, 148]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"reported case\"]], \"start\": [[20]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
11144696_9 | Both venlafaxine and trimipramine have been associated with seizures, mainly after overdose. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"overdose\", \"venlafaxine and trimipramine\"]], \"start\": [[83, 5]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"venlafaxine\"], [\"trimipramine\"]], \"start\": [[5], [21]], \"entity_id\": [\"T9\", \"T10\"]}, \"Dosage\": {\"text\": [[\"overdose\"]], \"start\": [[83]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"seizures\"]], \"start\": [[60]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
9291634_4 | Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and severe myalgias. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experienced\"]], \"start\": [[206]], \"entity_id\": [\"T15\"]}, \"Effect\": {\"text\": [[\"fever, infectious complications, gastrointestinal tract symptoms and severe myalgias\"]], \"start\": [[218]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"chemotherapy\", \"cytosine arabinoside (ARA-C)\"]], \"start\": [[85, 130]], \"entity_id\": [\"T14\"], \"Drug\": {\"text\": [[\"cytosine arabinoside\"]], \"start\": [[130]], \"entity_id\": [\"T18\"]}, \"Duration\": {\"text\": [[\"three-month\"]], \"start\": [[43]], \"entity_id\": [\"T19\"]}}, \"Subject\": {\"text\": [[\"five\"]], \"start\": [[201]], \"entity_id\": [\"T16\"], \"Population\": {\"text\": [[\"five\"]], \"start\": [[201]], \"entity_id\": [\"T17\"]}}}"
}
]
}
] |
14674674_2 | Infliximab-induced lupus in Crohn's disease: a case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Infliximab\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Infliximab\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[45]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"lupus\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
10660641_7 | The infection tended to subside with the AMPH administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"subside\"]], \"start\": [[24]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"AMPH administration\"]], \"start\": [[41]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"AMPH\"]], \"start\": [[41]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"infection tended\"]], \"start\": [[4]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17228132_2 | CONTEXT: Acute drug induced hepatitis has not been commonly associated with epidermal growth factor receptor (EGFR) inhibitors. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[60]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"epidermal growth factor receptor (EGFR) inhibitors\"]], \"start\": [[76]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"epidermal growth factor receptor\", \"inhibitors\"]], \"start\": [[76, 116]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Acute drug induced hepatitis\"]], \"start\": [[9]], \"entity_id\": [\"T6\"]}, \"Negated\": {\"text\": [[\"not\"]], \"start\": [[42]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
17873198_5 | We report a case of fatal pulmonary toxicity in a patient with advanced non-small cell lung cancer who received erlotinib. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"received\"]], \"start\": [[103]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"erlotinib\"]], \"start\": [[112]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"advanced non-small cell lung cancer\"]], \"start\": [[63]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"erlotinib\"]], \"start\": [[112]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"pulmonary toxicity\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient with advanced non-small cell lung cancer\"]], \"start\": [[48]], \"entity_id\": [\"T3\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[20]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
16200540_4 | We describe a patient with idiopathic RLS who developed augmentation after 8 months of levodopa treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[46]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with idiopathic RLS\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"augmentation\"]], \"start\": [[56]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"after 8 months of levodopa treatment\"]], \"start\": [[69]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"idiopathic RLS\"]], \"start\": [[27]], \"entity_id\": [\"T4\"]}, \"Time_elapsed\": {\"text\": [[\"8 months\"]], \"start\": [[75]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"levodopa\"]], \"start\": [[87]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
12923827_3 | This communication describes a patient who developed Schneiderian first-rank symptoms in the course of treatment with fluvoxamine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[43]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Schneiderian first-rank symptoms\"]], \"start\": [[53]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[118]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[118]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[29]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
3753891_2 | In addition to the recognized arrhythmic complications, the authors emphasize myocardial necrosis as a possible further manifestation of amsacrine-related cardiotoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[147]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"myocardial necrosis\", \"cardiotoxicity\"]], \"start\": [[78, 155]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"amsacrine\"]], \"start\": [[137]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"amsacrine\"]], \"start\": [[137]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[103]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
2857534_2 | The authors caution that treatment with alprazolam may be complicated by the induction of mania. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induction of\"]], \"start\": [[77]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"treatment with alprazolam\"]], \"start\": [[25]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"alprazolam\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"mania\"]], \"start\": [[90]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
17596682_2 | The use of rituximab has been uncommonly associated with delayed pulmonary toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[41]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"rituximab\"]], \"start\": [[11]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"rituximab\"]], \"start\": [[11]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"delayed pulmonary toxicity\"]], \"start\": [[57]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
18515982_6 | We believe that the acute renal failure in our patient was associated with anastrozole. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[59]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"acute renal failure\"]], \"start\": [[20]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[47]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"anastrozole\"]], \"start\": [[75]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"anastrozole\"]], \"start\": [[75]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
8656412_1 | On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and betamethasone, edema developed in both labia. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[103]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"edema\", \"in both labia\"]], \"start\": [[97, 113]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and betamethasone\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Duration\": {\"text\": [[\"the fifth day\"]], \"start\": [[3]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"magnesium sulfate\"], [\"nifedipine\"], [\"terbutaline\"], [\"betamethasone\"]], \"start\": [[35], [54], [66], [82]], \"entity_id\": [\"T10\", \"T11\", \"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[78]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"magnesium sulfate\"], [\"nifedipine\"], [\"terbutaline\"], [\"betamethasone\"]], \"start\": [[35], [54], [66], [82]], \"entity_id\": [\"T10\", \"T11\", \"T12\", \"T13\"]}}]}}"
}
]
}
] |
6159523_2 | Two patients with extrinsic asthma and coexistent insulin-dependent diabetes mellitus sustained an anaphylactoid reaction after the intravenous administration of 50% solution of dextrose. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[122]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"intravenous administration of 50% solution of dextrose\"]], \"start\": [[132]], \"entity_id\": [\"T8\"], \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[132]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"dextrose\"]], \"start\": [[178]], \"entity_id\": [\"T15\"]}}, \"Subject\": {\"text\": [[\"Two patients with extrinsic asthma and coexistent insulin-dependent diabetes mellitus\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"extrinsic asthma\"], [\"insulin-dependent diabetes mellitus\"]], \"start\": [[18], [50]], \"entity_id\": [\"T12\", \"T13\"]}}, \"Effect\": {\"text\": [[\"anaphylactoid reaction\"]], \"start\": [[99]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
8936932_3 | Cardiac arrest after esmolol administration: a review of acute beta-blocker toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[15]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"esmolol\"]], \"start\": [[21]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"esmolol\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Cardiac arrest\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
3680913_3 | We suggest that nicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[39]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"nicotinic acid\"]], \"start\": [[16]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"nicotinic acid\"]], \"start\": [[16]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"liver disease\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
17277758_3 | METHODS: Two patients with exudative age-related macular degeneration were treated sequentially with an intravitreal injection of bevacizumab and developed signs of severe but painless infectious endophthalmitis 2 days later. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[146]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"Two patients\"]], \"start\": [[9]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[9]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"intravitreal injection of bevacizumab\", \"2 days later\"]], \"start\": [[104, 212]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"exudative age-related macular degeneration\"]], \"start\": [[27]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"intravitreal injection\"]], \"start\": [[104]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"bevacizumab\"]], \"start\": [[130]], \"entity_id\": [\"T12\"]}, \"Time_elapsed\": {\"text\": [[\"2 days later.\"]], \"start\": [[212]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"infectious endophthalmitis\"]], \"start\": [[185]], \"entity_id\": [\"T9\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[165]], \"entity_id\": [\"T14\"], \"value\": \"High\"}}"
}
]
}
] |
2586773_1 | Ibuprofen-induced meningitis: detection of intrathecal IgG synthesis and immune complexes. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Ibuprofen\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Ibuprofen\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"meningitis\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
18020545_2 | Tardive oculogyric crisis during treatment with clozapine: report of three cases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[43]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Tardive oculogyric crisis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"clozapine\"]], \"start\": [[48]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[48]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"three cases\"]], \"start\": [[69]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[69]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
11506739_1 | Myasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis C. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Myasthenia gravis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"low-dose IFN-alpha therapy\"]], \"start\": [[25]], \"entity_id\": [\"T4\"], \"Dosage\": {\"text\": [[\"low-dose\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"IFN-alpha\"]], \"start\": [[34]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"chronic hepatitis C\"]], \"start\": [[56]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
12424571_2 | We herein report this rare case of acute onset of nephrotic syndrome during interferon-alpha retreatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[69]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"acute onset of nephrotic syndrome\"]], \"start\": [[35]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"interferon-alpha\"]], \"start\": [[76]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"interferon-alpha\"]], \"start\": [[76]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
7393795_2 | Para-aminosalicylic acid-induced hypoglycaemia in a patient with diabetic nephropathy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient with diabetic nephropathy\"]], \"start\": [[50]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"diabetic nephropathy\"]], \"start\": [[65]], \"entity_id\": [\"T4\"]}}, \"Treatment\": {\"text\": [[\"Para-aminosalicylic acid\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Para-aminosalicylic acid\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hypoglycaemia\"]], \"start\": [[33]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
3970339_2 | Ischaemia following selfadministered intra-arterial injection of methylphenidate and diamorphine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Ischaemia\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"selfadministered intra-arterial injection of methylphenidate and diamorphine\"]], \"start\": [[20]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"methylphenidate\"], [\"diamorphine\"]], \"start\": [[65], [85]], \"entity_id\": [\"T7\", \"T8\"]}, \"Route\": {\"text\": [[\"intra-arterial injection\"]], \"start\": [[37]], \"entity_id\": [\"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[81]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"methylphenidate\"], [\"diamorphine\"]], \"start\": [[65], [85]], \"entity_id\": [\"T7\", \"T8\"]}}]}}"
}
]
}
] |
9660541_2 | Mitomycin C-related hemolytic uremic syndrome in cancer patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Mitomycin C\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Mitomycin C\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"cancer\"]], \"start\": [[49]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hemolytic uremic syndrome\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"cancer patients\"]], \"start\": [[49]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
7549443_1 | The second had acute cystitis and was treated by sulphonamide and the third developed myopia coincident with metronidazole treatment for trichomonas vaginalis. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[76]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"myopia\"]], \"start\": [[86]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"metronidazole treatment\"]], \"start\": [[109]], \"entity_id\": [\"T14\"], \"Drug\": {\"text\": [[\"metronidazole\"]], \"start\": [[109]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"trichomonas vaginalis\"]], \"start\": [[137]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"the third\"]], \"start\": [[66]], \"entity_id\": [\"T15\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[38]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"sulphonamide\"]], \"start\": [[49]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"acute cystitis\"]], \"start\": [[15]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"sulphonamide\"]], \"start\": [[49]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
19669617_3 | Acute bilateral phrenic neuropathy following treatment with adalimumab. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[35]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Acute bilateral phrenic neuropathy\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"adalimumab\"]], \"start\": [[60]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"adalimumab\"]], \"start\": [[60]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
8921647_4 | Hypoxemia improved during continuous tolazoline infusion, but gastrointestinal bleeding occurred. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[88]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"gastrointestinal bleeding\"]], \"start\": [[62]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Hypoxemia improved during continuous tolazoline infusion\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"Hypoxemia\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"tolazoline\"]], \"start\": [[37]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[48]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
18176653_3 | BACKGROUND: NVP is a non-nucleoside reverse transcriptase inhibitor used in the treatment of Human Immunodeficiency Virus (HIV) infection. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"used\"]], \"start\": [[68]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"NVP\"]], \"start\": [[12]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"Human Immunodeficiency Virus (HIV) infection\"]], \"start\": [[93]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"NVP\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7393795_1 | A 62-year-old Indian with diabetic nephropathy controlled with metformin, developed miliary tuberculosis for which he was treated with rifampicin, isoniazid and ethambutol. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[74]], \"entity_id\": [\"T13\"]}, \"Effect\": {\"text\": [[\"miliary tuberculosis\"]], \"start\": [[84]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A 62-year-old Indian with diabetic nephropathy\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"62-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Race\": {\"text\": [[\"Indian\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"metformin\"]], \"start\": [[63]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"diabetic nephropathy\"]], \"start\": [[26]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"metformin\"]], \"start\": [[63]], \"entity_id\": [\"T10\"]}}}"
},
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[122]], \"entity_id\": [\"T15\"]}, \"Treatment\": {\"text\": [[\"rifampicin, isoniazid and ethambutol\"]], \"start\": [[135]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"miliary tuberculosis\"]], \"start\": [[84]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"ethambutol\"], [\"rifampicin\"], [\"isoniazid\"]], \"start\": [[161], [135], [147]], \"entity_id\": [\"T14\", \"T18\", \"T19\"]}, \"Combination\": [{\"event_id\": \"E3\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[157]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"ethambutol\"], [\"isoniazid\"], [\"rifampicin\"]], \"start\": [[161], [147], [135]], \"entity_id\": [\"T14\", \"T19\", \"T18\"]}}]}}"
}
]
}
] |
8438851_1 | A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[81]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"continuous intravenous infusion of vasopressin\"]], \"start\": [[105]], \"entity_id\": [\"T4\"], \"Route\": {\"text\": [[\"continuous intravenous infusion\"]], \"start\": [[105]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"vasopressin\"]], \"start\": [[140]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"acute esophageal variceal bleeding\"]], \"start\": [[15]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"A patient with acute esophageal variceal bleeding\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"fatal rhabdomyolysis\"]], \"start\": [[60]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[60]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
6159523_7 | Preliminary results suggest that the higher concentrations of dextrose induce increased histamine release from blood cells, and that this phenomenon is more marked in diabetic, and particularly diabetic-allergic, individuals. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induce\"]], \"start\": [[71]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"higher concentrations of dextrose\"]], \"start\": [[37]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"dextrose\"]], \"start\": [[62]], \"entity_id\": [\"T6\"]}, \"Dosage\": {\"text\": [[\"higher concentrations\"]], \"start\": [[37]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"increased histamine release from blood cells\"]], \"start\": [[78]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"diabetic, and particularly diabetic-allergic, individuals\"]], \"start\": [[167]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"diabetic\"], [\"diabetic-allergic\"]], \"start\": [[167], [194]], \"entity_id\": [\"T7\", \"T1\"]}}}"
}
]
}
] |
12243603_12 | All patients beginning HMG-CoA reductase inhibitor therapy should be counseled regarding the signs and symptoms of muscle injury; particular attention should be paid to those patients who are taking medications that may interact. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"regarding\"]], \"start\": [[79]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"All patients\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"HMG-CoA reductase inhibitor\"]], \"start\": [[23]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"HMG-CoA reductase inhibitor\"]], \"start\": [[23]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"the signs and symptoms of muscle injury\"]], \"start\": [[89]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
16498048_4 | Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[17]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Interferon-alpha\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Interferon-alpha\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hyperthyroidism\", \"Graves' disease\"]], \"start\": [[25, 98]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16708747_1 | Acute severe intoxication with carbamazepine is associated with seizures, coma and respiratory depression. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[48]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"carbamazepine\"]], \"start\": [[31]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[31]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"Acute severe intoxication\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |